coya therapeutics inc - COYA

COYA

Close Chg Chg %
3.13 -0.13 -4.15%

Closed Market

3.00

-0.13 (4.15%)

Volume: 98.96K

Last Updated:

Nov 16, 2026, 4:00 PM EDT

Company Overview: coya therapeutics inc - COYA

COYA Key Data

Open

$3.18

Day Range

2.96 - 3.13

52 Week Range

2.74 - 6.62

Market Cap

$76.71M

Shares Outstanding

23.46M

Public Float

20.01M

Beta

0.70

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.33

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

181.70K

 

COYA Performance

1 Week
 
4.68%
 
1 Month
 
-26.35%
 
3 Months
 
-34.66%
 
1 Year
 
-46.68%
 
5 Years
 
N/A
 

COYA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About coya therapeutics inc - COYA

Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing proprietary new therapies to enhance the function of regulatory T cells. Its pipeline includes Treg Modifying Biologics, Allogeneic Treg-Derived Exosomes, and Autologous Treg Cell Therapy. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.

COYA At a Glance

Coya Therapeutics, Inc.
5850 San Felipe Street
Houston, Texas 77057
Phone 1-800-587-8170 Revenue 7.95M
Industry Biotechnology Net Income -21,226,107.00
Sector Health Technology 2025 Sales Growth 123.568%
Fiscal Year-end 12 / 2026 Employees 8
View SEC Filings

COYA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 12.212
Price to Book Ratio 2.822
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -2.481
Enterprise Value to Sales 6.319
Total Debt to Enterprise Value N/A

COYA Efficiency

Revenue/Employee 993,219.125
Income Per Employee -2,653,263.375
Receivables Turnover N/A
Total Asset Turnover 0.169

COYA Liquidity

Current Ratio 8.505
Quick Ratio 8.505
Cash Ratio 7.974

COYA Profitability

Gross Margin 99.656
Operating Margin -255.05
Pretax Margin -267.099
Net Margin -267.138
Return on Assets -45.02
Return on Equity -51.392
Return on Total Capital -49.331
Return on Invested Capital -51.392

COYA Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Coya Therapeutics Inc - COYA

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- 6.00M 3.55M 7.95M
Sales Growth
- - -40.79% +123.57%
-
Cost of Goods Sold (COGS) incl D&A
27.36K 27.36K 27.36K 27.36K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
27.36K 27.36K 27.36K 27.36K
Depreciation
27.36K 27.36K 27.36K 27.36K
Amortization of Intangibles
- - - -
-
COGS Growth
- - - +69.60%
-
Gross Income
(27.36K) 5.97M 3.53M 7.92M
Gross Income Growth
-69.60% +21,937.09% -40.97% +124.53%
Gross Profit Margin
- +99.54% +99.23% +99.66%
2022 2023 2024 2025 5-year trend
SG&A Expense
9.26M 13.34M 20.75M 28.18M
Research & Development
4.41M 5.50M 11.87M 16.73M
Other SG&A
4.85M 7.83M 8.89M 11.45M
SGA Growth
+90.75% +44.01% +55.62% +35.82%
Other Operating Expense
- - - -
-
Unusual Expense
3.02M 543.19K 25.00K 2.29M
EBIT after Unusual Expense
(12.31M) (7.90M) (17.25M) (22.56M)
Non Operating Income/Expense
63.67K 639.36K 1.65M 1.33M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(12.24M) (7.26M) (15.60M) (21.22M)
Pretax Income Growth
-150.31% +40.68% -114.77% -36.04%
Pretax Margin
- -121.02% -438.96% -267.10%
Income Tax
- 723.85K (720.29K) 3.09K
Income Tax - Current - Domestic
- 723.85K (720.29K) 3.09K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(12.24M) (7.99M) (14.88M) (21.23M)
Minority Interest Expense
- - - -
-
Net Income
(12.24M) (7.99M) (14.88M) (21.23M)
Net Income Growth
-150.31% +34.77% -86.29% -42.64%
Net Margin Growth
- -133.08% -418.70% -267.14%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(12.24M) (7.99M) (14.88M) (21.23M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(12.24M) (7.99M) (14.88M) (21.23M)
EPS (Basic)
-1.2309 -0.7859 -0.9765 -1.2687
EPS (Basic) Growth
-143.55% +36.15% -24.25% -29.92%
Basic Shares Outstanding
9.95M 10.16M 15.24M 16.73M
EPS (Diluted)
-1.2309 -0.7859 -0.9765 -1.2687
EPS (Diluted) Growth
-143.55% +36.15% -24.25% -29.92%
Diluted Shares Outstanding
9.95M 10.16M 15.24M 16.73M
EBITDA
(9.26M) (7.33M) (17.20M) (20.24M)
EBITDA Growth
-90.75% +20.81% -134.53% -17.68%
EBITDA Margin
- -122.17% -483.88% -254.71%

Snapshot

Average Recommendation BUY Average Target Price 14.75
Number of Ratings 7 Current Quarters Estimate -0.441
FY Report Date 12 / 2026 Current Year's Estimate -1.481
Last Quarter’s Earnings -0.45 Median PE on CY Estimate N/A
Year Ago Earnings -1.27 Next Fiscal Year Estimate -1.518
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 5 7 6
Mean Estimate -0.44 -0.44 -1.48 -1.52
High Estimates -0.32 -0.32 -1.32 -0.84
Low Estimate -0.51 -0.55 -1.57 -2.52
Coefficient of Variance -16.51 -22.62 -6.53 -41.60

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 7
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Coya Therapeutics Inc - COYA

Date Name Shares Transaction Value
Jan 8, 2026 Wilbur Louis Ross Director 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Dov A. Goldstein Director 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Dieter Weinand Director 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Anabella Villalobos Director 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 8, 2026 Ann L. Lee Director 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Coya Therapeutics Inc in the News